Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc G Berger

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Molecular Genetics and Metabolism|August 19, 2023
Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO studyFabrice Camou, Audrey Lagadec, Angela Coutinho, et al.
British Journal of Haematology|December 22, 2017
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phasePascale Cony-Makhoul, Martine Gardembas, Valérie Coiteux, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 31, 2024
Deciphering metabolic shifts in Gaucher disease type 1: a multi-omics studyFranklin Ducatez, Marc G Berger, Carine Pilon, et al.
British Journal of Haematology|January 10, 2012
The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variableJuliette Berger, Jérôme Stirnemann, Céline Bourgne, et al.
BMC Cancer|July 5, 2024
Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
Clinical Therapeutics|January 30, 2010
Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher diseaseNathalie Boiret-Dupré, Stéphane Descamps, Marie Ange Coudoré, et al.
Orphanet Journal of Rare Diseases|June 6, 2025
SplenoMegaly study (SMS): exploring the etiologies for "unexplained" splenomegalies in the real worldGuillaume Denis, Louis Terriou, Thomas Sené, et al.
BMC Cancer|May 30, 2024
Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
British Journal of Haematology|September 28, 2007
Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapyRichard Veyrat-Masson, Nathalie Boiret-Dupré, Chantal Rapatel, et al.
Haematologica|February 1, 2020
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant dataTatiana Raskovalova, Patrick B Deegan, Pramod K Mistry, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Molecular Genetics and Metabolism|August 19, 2023
Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO studyFabrice Camou, Audrey Lagadec, Angela Coutinho, et al.
British Journal of Haematology|December 22, 2017
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phasePascale Cony-Makhoul, Martine Gardembas, Valérie Coiteux, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 31, 2024
Deciphering metabolic shifts in Gaucher disease type 1: a multi-omics studyFranklin Ducatez, Marc G Berger, Carine Pilon, et al.
British Journal of Haematology|January 10, 2012
The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variableJuliette Berger, Jérôme Stirnemann, Céline Bourgne, et al.
BMC Cancer|July 5, 2024
Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
Clinical Therapeutics|January 30, 2010
Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher diseaseNathalie Boiret-Dupré, Stéphane Descamps, Marie Ange Coudoré, et al.
Orphanet Journal of Rare Diseases|June 6, 2025
SplenoMegaly study (SMS): exploring the etiologies for "unexplained" splenomegalies in the real worldGuillaume Denis, Louis Terriou, Thomas Sené, et al.
BMC Cancer|May 30, 2024
Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
British Journal of Haematology|September 28, 2007
Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapyRichard Veyrat-Masson, Nathalie Boiret-Dupré, Chantal Rapatel, et al.
Haematologica|February 1, 2020
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant dataTatiana Raskovalova, Patrick B Deegan, Pramod K Mistry, et al.
Pageof 6